Anna CzÅ‚onkowska

List of Publications by Year
in descending order

312	17,706	25034 57	17592 121
papers	citations	h-index	g-index

325	325	325	19892
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE) Tj ETQq1 1 0.784314 rgBT /Overlo	13.7	2,565
2	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, The, 2016, 388, 761-775.	13.7	1,414
3	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, The, 2012, 379, 2352-2363.	13.7	1,018
4	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine, 2018, 378, 2191-2201.	27.0	730
5	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
6	Wilson disease. Nature Reviews Disease Primers, 2018, 4, 21.	30.5	466
7	The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse. Experimental Neurology, 1999, 156, 50-61.	4.1	338
8	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet, The, 2018, 391, 2107-2115.	13.7	309
9	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2014, 20, 705-716.	3.0	295
10	Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology, 1998, 39, 167-180.	2.0	261
11	Frequency and Prognostic Value of Cognitive Disorders in Stroke Patients. Dementia and Geriatric Cognitive Disorders, 2008, 26, 356-363.	1.5	255
12	Influence of Gender on Baseline Features and Clinical Outcomes among 17,370 Patients with Confirmed Ischaemic Stroke in the International Stroke Trial. Neuroepidemiology, 2005, 24, 123-128.	2.3	251
13	Microglial Reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Induced Parkinson's Disease Mice Model. Experimental Neurology, 1996, 5, 137-143.	1.7	245
14	Late-Onset Wilsonâ€™s Disease. Gastroenterology, 2007, 132, 1294-1298.	1.3	227
15	Effects of long-term treatment in Wilson's disease withd-penicillamine and zinc sulphate. Journal of Neurology, 1996, 243, 269-273.	3.6	172
16	MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Strokeâ€”A Comprehensive Review and Bioinformatic Analysis. Cells, 2018, 7, 249.	4.1	131
17	Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clinical Genetics, 2005, 68, 524-532.	2.0	124
18	Gender differences in Wilson's disease. Journal of the Neurological Sciences, 2012, 312, 31-35.	0.6	119

#	Article	IF	Citations
19	Early neurological worsening in patients with Wilson's disease. Journal of the Neurological Sciences, 2015, 355, 162-167.	0.6	116
20	Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. Lancet Neurology, The, 2018, 17, 587-596.	10.2	114
21	Dâ€penicillamine versus zinc sulfate as firstâ€line therapy for Wilson's disease. European Journal of Neurology, 2014, 21, 599-606.	3.3	113
22	Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases. Current Pharmaceutical Design, 2005, 11, 1017-1030.	1.9	112
23	Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. The Lancet Gastroenterology and Hepatology, 2017, 2, 869-876.	8.1	110
24	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology, 2019, 69, 1464-1476.	7.3	110
25	Risk factors for falls in stroke patients during inpatient rehabilitation. Clinical Rehabilitation, 2009, 23, 176-188.	2.2	107
26	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 2004, 4, 1307-1318.	3.8	106
27	Factors Influencing In-Hospital Delay in Treatment With Intravenous Thrombolysis. Stroke, 2012, 43, 1578-1583.	2.0	104
28	Intracerebral Hematoma Morphologic Appearance on Noncontrast Computed Tomography Predicts Significant Hematoma Expansion. Stroke, 2015, 46, 3111-3116.	2.0	103
29	Gender Differences in Neurological Disease: Role of Estrogens and Cytokines. Endocrine, 2006, 29, 243-256.	2.2	98
30	Microglia and microglia-derived brain macrophages in culture: generation from axotomized rat facial nuclei, identification and characterization in vitro. Brain Research, 1989, 492, 1-14.	2.2	97
31	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	13.7	96
32	Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology, 2021, 96, e2824-e2838.	1.1	95
33	Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Movement Disorders, 2008, 23, 54-62.	3.9	94
34	Transcranial Magnetic Stimulation Combined With Physiotherapy in Rehabilitation of Poststroke Hemiparesis. Neurorehabilitation and Neural Repair, 2012, 26, 1072-1079.	2.9	94
35	Wilsonâ€™s diseaseâ€”cause of mortality in 164 patients during 1992â€“2003 observation period. Journal of Neurology, 2005, 252, 698-703.	3.6	89
36	The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials, 2008, 9, 37.	1.6	86

#	Article	IF	Citations
37	Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. Movement Disorders, 2002, 17, 1077-1083.	3.9	83
38	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal, 2016, 1, 146-154.	5.5	83
39	Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor-? by HLA-DR2+ T cells. Annals of Neurology, 1995, 38, 723-730.	5.3	81
40	Transcranial Magnetic Stimulation Combined with Speech and Language Training in Early Aphasia Rehabilitation: A Randomized Double-Blind Controlled Pilot Study. Topics in Stroke Rehabilitation, 2013, 20, 250-261.	1.9	81
41	Inflammation and gliosis in neurological diseases â€“ clinical implications. Journal of Neuroimmunology, 2011, 231, 78-85.	2.3	78
42	Hepatobiliary malignancies in Wilson disease. Liver International, 2015, 35, 1615-1622.	3.9	78
43	The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Molecular Neurobiology, 2021, 58, 329-347.	4.0	78
44	Brain metal accumulation in Wilson's disease. Journal of the Neurological Sciences, 2013, 329, 55-58.	0.6	77
45	Wilson Disease and Other Neurodegenerations with Metal Accumulations. Neurologic Clinics, 2015, 33, 175-204.	1.8	76
46	Immunological observations on patients with acute cerebral vascular disease. Journal of the Neurological Sciences, 1979, 43, 455-464.	0.6	74
47	Alteplase for Acute Ischemic Stroke. Stroke, 2015, 46, 746-756.	2.0	74
48	Monozygotic female twins discordant for phenotype of Wilson's disease. Movement Disorders, 2009, 24, 1066-1069.	3.9	72
49	Compliant treatment with antiâ€copper agents prevents clinically overt <scp>W</scp>ilson's disease in preâ€symptomatic patients. European Journal of Neurology, 2014, 21, 332-337.	3.3	70
50	Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Medical Science Monitor, 2002, 8, RA165-77.	1.1	69
51	p.H1069Q mutation inATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Movement Disorders, 2006, 21, 245-248.	3.9	68
52	Psychiatric manifestations in Wilsonâ€™s disease: possibilities and difficulties for treatment. Therapeutic Advances in Psychopharmacology, 2018, 8, 199-211.	2.7	68
53	Late onset Wilson's disease: Therapeutic implications. Movement Disorders, 2008, 23, 896-898.	3.9	67
54	Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Naming Abilities in Early-Stroke Aphasic Patients: A Prospective, Randomized, Double-Blind Sham-Controlled Study. Scientific World Journal, The, 2012, 2012, 1-8.	2.1	66

#	Article	IF	Citations
55	Effects of Repeated Anodal tDCS Coupled With Cognitive Training for Patients With Severe Traumatic Brain Injury. Journal of Head Trauma Rehabilitation, 2014, 29, E20-E29.	1.7	65
56	New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. Journal of the Neurological Sciences, 2009, 283, 214-218.	0.6	61
57	Spot Sign Number Is the Most Important Spot Sign Characteristic for Predicting Hematoma Expansion Using First-Pass Computed Tomography Angiography. Stroke, 2013, 44, 972-977.	2.0	61
58	Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke. Stroke, 2014, 45, 770-775.	2.0	60
59	Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI â€“ histopathological study. Neuropathology and Applied Neurobiology, 2017, 43, 514-532.	3.2	60
60	The International Stroke Trial database. Trials, 2011, 12, 101.	1.6	59
61	Neurologic impairment in Wilson disease. Annals of Translational Medicine, 2019, 7, S64-S64.	1.7	58
62	Persistence with treatment in patients with Wilson disease. Neurologia I Neurochirurgia Polska, 2010, 44, 260-263.	1.2	54
63	Early stroke-related deep venous thrombosis: risk factors and influence on outcome. Journal of Thrombosis and Thrombolysis, 2011, 32, 96-102.	2.1	54
64	Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 101-119.	1.8	52
65	Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-Î± polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2011, 236, 87-92.	2.3	51
66	Venous Phase of Computed Tomography Angiography Increases Spot Sign Detection, but Intracerebral Hemorrhage Expansion Is Greater in Spot Signs Detected in Arterial Phase. Stroke, 2014, 45, 734-739.	2.0	51
67	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. International Journal of Stroke, 2016, 11, 683-694.	5.9	50
68	Ultraearly hematoma growth in active intracerebral hemorrhage. Neurology, 2016, 87, 357-364.	1.1	50
69	Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis. Stroke, 2016, 47, 652-658.	2.0	48
70	Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilsonâ€™s disease. Journal of Hepatology, 2011, 55, 913-919.	3.7	47
71	Wilson disease â€“ currently used anticopper therapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 181-191.	1.8	47
72	Elevated Levels of Anti-Heat Shock Protein Antibodies in Patients with Cerebral Ischemia. Cerebrovascular Diseases, 2001, 12, 235-239.	1.7	46

#	Article	IF	Citations
73	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1673-1682.	1.6	46
74	Intravenous Alteplase in Ischemic Stroke Patients not Fully Adhering to the Current Drug License in Central and Eastern Europe. International Journal of Stroke, 2012, 7, 615-622.	5.9	44
75	Wilsonâ€™s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1053-1061.	1.9	44
76	Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilsonâ€™s Disease Rating Scale. BMC Neurology, 2018, 18, 34.	1.8	43
77	Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Movement Disorders, 2020, 35, 994-1001.	3.9	43
78	Apolipoprotein E gene (APOE) genotype in Wilsonâ€™s disease: Impact on clinical presentation. Parkinsonism and Related Disorders, 2012, 18, 367-369.	2.2	42
79	The effect of gender on brain MRI pathology in Wilsonâ€™s disease. Metabolic Brain Disease, 2013, 28, 69-75.	2.9	42
80	Anodal transcranial direct current stimulation in early rehabilitation of patients with post-stroke non-fluent aphasia: A randomized, double-blind, sham-controlled pilot study. Restorative Neurology and Neuroscience, 2013, 31, 761-771.	0.7	42
81	Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Research, 2004, 1019, 144-151.	2.2	41
82	Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurological Research, 1999, 21, 653-657.	1.3	40
83	Underfunding of Stroke Research. Stroke, 2004, 35, 2368-2371.	2.0	40
84	Symptomatic treatment of neurologic symptoms in Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 211-223.	1.8	39
85	Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 2009, 1261, 7-19.	2.2	38
86	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials, 2011, 12, 252.	1.6	38
87	Wholeâ€exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype. Liver International, 2019, 39, 177-186.	3.9	38
88	Clinical manifestations of Wilson disease in organs other than the liver and brain. Annals of Translational Medicine, 2019, 7, S62-S62.	1.7	38
89	BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the polish population. Gender differences. Journal of Neuroimmunology, 2008, 193, 170-172.	2.3	36
90	Hyperperfusion Syndrome after Carotid Endarterectomy and Carotid Stenting. Cerebrovascular Diseases, 2013, 35, 531-537.	1.7	36

#	Article	IF	Citations
91	Effect of medical complications on the after-stroke rehabilitation outcome. NeuroRehabilitation, 2017, 40, 223-232.	1.3	36
92	Middle-aged heterozygous carriers of Wilsonâ€™s disease do not present with significant phenotypic deviations related to copper metabolism. Journal of Genetics, 2010, 89, 463-467.	0.7	35
93	The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease. Pharmacological Reports, 2014, 66, 660-669.	3.3	35
94	Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilsonâ€™s disease.. Neuropsychology, 2015, 29, 25-30.	1.3	34
95	Wilson diseaseâ€”treatment perspectives. Annals of Translational Medicine, 2019, 7, S68-S68.	1.7	34
96	Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients. Neurologia I Neurochirurgia Polska, 2007, 41, 1-12.	1.2	34
97	MR spectroscopy in monitoring the treatment of Wilson's disease patients. Movement Disorders, 2008, 23, 1560-1566.	3.9	33
98	Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiologiae Experimentalis, 2003, 63, 117-26.	0.7	33
99	No effects of anodal transcranial direct stimulation on language abilities in early rehabilitation of post-stroke aphasic patients. Neurologia I Neurochirurgia Polska, 2013, 47, 414-422.	1.2	32
100	Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate. Neurologia I Neurochirurgia Polska, 2014, 48, 214-218.	1.2	32
101	Glyceryl Trinitrate for Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 44-52.	2.0	32
102	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics and Chromatin, 2019, 12, 10.	3.9	32
103	Oxfordshire Community Stroke Project Clinical Stroke Syndrome and Appearances of Tissue and Vascular Lesions on Pretreatment CT in Hyperacute Ischemic Stroke Among the First 510 Patients in the Third International Stroke Trial (IST-3). Stroke, 2009, 40, 743-748.	2.0	31
104	BDNF â^'270 C>T polymorphisms might be associated with stroke type and BDNF â^'196 G>A corresponds to early neurological deficit in hemorrhagic stroke. Journal of Neuroimmunology, 2012, 249, 71-75.	2.3	31
105	Encephalopathy in Wilson Disease: Copper Toxicity or Liver Failure?. Journal of Clinical and Experimental Hepatology, 2015, 5, S88-S95.	0.9	31
106	The sunflower cataract in Wilsonâ€™s disease: pathognomonic sign or rare finding?. Acta Neurologica Belgica, 2016, 116, 325-328.	1.1	31
107	Late Onset of Wilson's Disease. Archives of Neurology, 1981, 38, 729.	4.5	30
108	The Activity of Malignancy May Determine Stroke Pattern in Cancer Patients. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 778-783.	1.6	30

#	Article	IF	Citations
109	Persistence with treatment for Wilson disease: a retrospective study. BMC Neurology, 2019, 19, 278.	1.8	30
110	Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review. Molecular Neurobiology, 2021, 58, 1664-1682.	4.0	30
111	Immunological changes in the MPTP-induced Parkinson's disease mouse model. Journal of Neuroimmunology, 1993, 42, 33-37.	2.3	29
112	Acute Ischemic Stroke Care and Outcome in Centers Participating in the Polish National Stroke Prevention and Treatment Registry. Stroke, 2006, 37, 1837-1843.	2.0	29
113	Neurological presentation of Wilson's disease in a patient after liver transplantation. Movement Disorders, 2008, 23, 743-746.	3.9	29
114	Cerebral vasomotor reactivity in neurodegenerative diseases. Neurologia I Neurochirurgia Polska, 2016, 50, 455-462.	1.2	29
115	Clinical features of hemolysis, elevated liver enzymes, and low platelet count syndrome in undiagnosed Wilson disease: report of two cases. Archives of Gynecology and Obstetrics, 2010, 281, 129-134.	1.7	28
116	Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease. Pharmacological Reports, 2013, 65, 44-49.	3.3	28
117	Other organ involvement and clinical aspects of Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 157-169.	1.8	28
118	Does brain degeneration in Wilson disease involve not only copper but also iron accumulation?. Neurologia I Neurochirurgia Polska, 2013, 47, 542-546.	1.2	27
119	Association between BDNF-196 G>A and BDNF-270 C>T polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation outcome after ischemic stroke. NeuroRehabilitation, 2013, 32, 573-582.	1.3	27
120	Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurologica Scandinavica, 2014, 130, 305-311.	2.1	27
121	Safety of Statin Pretreatment in Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke, 2015, 46, 2681-2684.	2.0	27
122	Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry. Journal of Neurology, 2017, 264, 912-920.	3.6	27
123	Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome. Thrombosis and Haemostasis, 2017, 117, 1440-1447.	3.4	27
124	Brain volume is related to neurological impairment and to copper overload in Wilsonâ€™s disease. Neurological Sciences, 2019, 40, 2089-2095.	1.9	27
125	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2273-2279.	1.6	27
126	Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinsonâ€™s Disease. NeuroImmunoModulation, 2007, 14, 255-265.	1.8	26

#	Article	IF	Citations
127	Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2009, 214, 113-117.	2.3	26
128	Optical coherence tomography and electrophysiology of retinal and visual pathways in Wilsonâ€™s disease. Metabolic Brain Disease, 2016, 31, 405-415.	2.9	26
129	Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver International, 2018, 38, 1860-1866.	3.9	26
130	Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature. Metabolomics, 2019, 15, 43.	3.0	26
131	Infections Up to 76ÂDays After Stroke Increase Disability and Death. Translational Stroke Research, 2017, 8, 541-548.	4.2	25
132	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. Heart, 2021, 107, 282-289.	2.9	25
133	Lenticular nucleus hyperechogenicity in Wilsonâ€™s disease reflects local copper, but not iron accumulation. Journal of Neural Transmission, 2014, 121, 1273-1279.	2.8	24
134	Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod. Neurologia I Neurochirurgia Polska, 2017, 51, 156-162.	1.2	24
135	Pulse Pressure â€“ Independent Predictor of Poor Early Outcome and Mortality following Ischemic Stroke. Cerebrovascular Diseases, 2009, 27, 187-192.	1.7	23
136	Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson's disease. Movement Disorders, 2008, 23, 2067-2073.	3.9	22
137	Incidence and case fatality rates of first-ever stroke â€“ comparison of data from two prospective population-based studies conducted in Warsaw. Neurologia I Neurochirurgia Polska, 2011, 45, 207-212.	1.2	22
138	Infections and Ischemic Stroke Outcome. Neurology Research International, 2011, 2011, 1-8.	1.3	22
139	Influence ofIL-1RNIntron 2 Variable Number of Tandem Repeats (VNTR) Polymorphism on the Age at Onset of Neuropsychiatric Symptoms in Wilson's Disease. International Journal of Neuroscience, 2011, 121, 8-15.	1.6	22
140	Concordance rates of Wilson's disease phenotype among siblings. Journal of Inherited Metabolic Disease, 2014, 37, 131-135.	3.6	22
141	Polymorphisms of metal transporter genes DMT1 and ATP7A in Wilson's disease. Journal of Trace Elements in Medicine and Biology, 2014, 28, 8-12.	3.0	22
142	Impact ofBDNF-196 G>A andBDNF-270 C>T Polymorphisms on Stroke Rehabilitation Outcome: Sex and Age Differences. Topics in Stroke Rehabilitation, 2014, 21, S33-S41.	1.9	22
143	Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12. Parkinsonism and Related Disorders, 2017, 39, 71-76.	2.2	22
144	Optical coherence tomography as a marker of neurodegeneration in patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2017, 117, 867-871.	1.1	22

#	Article	IF	Citations
145	Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes. International Journal of Molecular Sciences, 2019, 20, 5937.	4.1	22
146	Leukoaraiosis and stroke outcome. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 336-340.	1.6	21
147	Agreement between the clinical Oxfordshire Community Stroke Project classification and CT findings in Poland. European Journal of Neurology, 2004, 11, 91-96.	3.3	21
148	Polymorphisms in the factor VII gene and ischemic stroke in young adults. Blood Coagulation and Fibrinolysis, 2010, 21, 442-447.	1.0	21
149	WTX101 â€“ an investigational drug for the treatment of Wilson disease. Expert Opinion on Investigational Drugs, 2018, 27, 561-567.	4.1	21
150	Deep Venous Thrombosis in Acute Stroke Patients. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 258-264.	1.7	20
151	Self-Rated Emotional Functioning of Patients With Neurological or Asymptomatic Form of Wilsonâ€™s Disease. Clinical Neuropsychologist, 2003, 17, 367-373.	2.3	19
152	Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated. Emergency Medicine Journal, 2007, 24, 96-99.	1.0	19
153	Management of ischemic stroke in Central and Eastern Europe. International Journal of Stroke, 2015, 10, 125-127.	5.9	19
154	The accuracy of prehospital diagnosis of acute cerebrovascular accidents: an observational study. Archives of Medical Science, 2015, 3, 530-535.	0.9	19
155	Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event. Stroke, 2015, 46, 3184-3189.	2.0	19
156	Immunological observations on patients with Wilson's disease. Journal of the Neurological Sciences, 1976, 29, 411-421.	0.6	18
157	Knowledge of Risk Factors and Stroke Symptoms among Nonstroke Patients. European Neurology, 2012, 67, 220-225.	1.4	18
158	Families with Wilson's disease in subsequent generations: Clinical and genetic analysis. Movement Disorders, 2014, 29, 1828-1832.	3.9	18
159	Small intracerebral hemorrhages have a low spot sign prevalence and are less likely to expand. International Journal of Stroke, 2016, 11, 191-197.	5.9	18
160	A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase. Journal of Hepatology, 2017, 67, 1026-1030.	3.7	18
161	Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease. Human Molecular Genetics, 2018, 27, 3854-3869.	2.9	18
162	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 2386-2394.	2.0	18

#	Article	IF	Citations
163	High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. Journal of Neuroimmunology, 2006, 176, 134-140.	2.3	17
164	Informed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudes. Trials, 2008, 9, 45.	1.6	17
165	Heterozygous carriers for Wilsonâ€™s diseaseâ€”magnetic spectroscopy changes in the brain. Metabolic Brain Disease, 2009, 24, 463-468.	2.9	17
166	Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 502-506.	1.2	17
167	Gene variants encoding proteins involved in antioxidant defense system and the clinical expression of Wilson disease. Liver International, 2015, 35, 215-222.	3.9	17
168	Evolution of diagnostic criteria for multiple sclerosis. Neurologia I Neurochirurgia Polska, 2015, 49, 313-321.	1.2	17
169	Cardiac assessment in Wilsonâ€™s disease patients based on electrocardiography and echocardiography examination. Archives of Medical Science, 2019, 15, 857-864.	0.9	17
170	Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland. Neurologia I Neurochirurgia Polska, 2012, 46, 3-14.	1.2	16
171	Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction. Croatian Medical Journal, 2016, 57, 548-557.	0.7	16
172	Perihematomal Edema Is Greater in the Presence of a Spot Sign but Does Not Predict Intracerebral Hematoma Expansion. Stroke, 2016, 47, 350-355.	2.0	16
173	Measurement of Nutritional Status Using Body Mass Index, Waist-to-Hip Ratio, and Waist Circumference to Predict Treatment Outcome in Females and Males with Acute First-Ever Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 132-139.	1.6	16
174	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Movement Disorders, 2022, 37, 1074-1079.	3.9	16
175	Effect of Naloxone on Acute Stroke. Pharmacopsychiatry, 1988, 21, 98-100.	3.3	15
176	Advanced atherosclerosis of the aortic arch is uncommon in ischemic stroke: An autopsy study. Neurological Research, 2002, 24, 491-494.	1.3	15
177	High early case fatality after ischaemic stroke in Poland: Exploration of possible explanations in the International Stroke Trial. Journal of the Neurological Sciences, 2002, 202, 53-57.	0.6	15
178	Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinsonâ€™s disease. Neuroscience, 2005, 131, 247-254.	2.3	15
179	Efficacy and Safety of Botulinum Type A Toxin in Adductor Spasticity Due to Multiple Sclerosis. Journal of Musculoskeletal Pain, 2008, 16, 175-188.	0.3	15
180	Pharmacotherapy in stroke rehabilitation. Expert Opinion on Pharmacotherapy, 2009, 10, 1249-1259.	1.8	15

#	Article	IF	Citations
181	Hyperdense Cerebral Artery Computed Tomography Sign Is Associated with Stroke Severity Rather than Stroke Subtype. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2533-2539.	1.6	15
182	MR image mimicking the â€œeye of the tigerâ€•sign in Wilsonâ€™s disease. Journal of Neurology, 2014, 261, 1025-1027.	3.6	15
183	Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. Functional Neurology, 2014, 29, 23-9.	1.3	15
184	A study of haemolysis in Wilson's disease. Journal of the Neurological Sciences, 1972, 16, 303-314.	0.6	14
185	Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis. European Journal of Neurology, 1999, 6, 347-352.	3.3	14
186	Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-?-1a treatment in multiple sclerosis patients. Journal of Neurology, 2003, 250, 1229-1236.	3.6	14
187	Ibuprofen and the mouse model of Parkinson's disease. Annals of Neurology, 2006, 59, 988-989.	5.3	14
188	Weekend versus weekday admissions in Polish stroke centres â€“ could admission day affect prognosis in Polish ischaemic stroke patients?. Neurologia I Neurochirurgia Polska, 2012, 46, 15-21.	1.2	14
189	Intestinal expression of metal transporters in Wilsonâ€™s disease. BioMetals, 2013, 26, 925-934.	4.1	14
190	Lithium Treatment of a Bipolar Patient with Wilson's Disease: A Case Report. Pharmacopsychiatry, 2013, 46, 120-121.	3.3	14
191	Neurological manifestations in Wilsonâ€™s disease â€“possible treatment options for symptoms. Expert Opinion on Orphan Drugs, 2016, 4, 719-728.	0.8	14
192	Evaluation of liver fibrosis in patients with Wilsonâ€™s disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 535-540.	1.6	14
193	Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilsoni¿½s disease. Functional Neurology, 2015, 30, 264-8.	1.3	14
194	Ten Years of Stroke Programmes in Poland: Where Did we Start? Where Did we Get To?. International Journal of Stroke, 2010, 5, 414-416.	5.9	13
195	Eye of the tiger sign in a 23year patient with mitochondrial membrane protein associated neurodegeneration. Journal of the Neurological Sciences, 2015, 352, 110-111.	0.6	13
196	Frequencies of initial gait disturbances and falls in 100 Wilson's disease patients. Gait and Posture, 2015, 42, 601-603.	1.4	13
197	Embolic strokes of undetermined source in a cohort of Polish stroke patients. Neurological Sciences, 2018, 39, 1041-1047.	1.9	13
198	The influence of prolonged treatment with D-penicillamine on the immune response in Wilson's disease. European Journal of Clinical Pharmacology, 1977, 12, 265-271.	1.9	12

#	Article	IF	Citations
199	APOE Genotype and Serum Cholesterol in Predicting Risk for Early Death from Ischemic Stroke in Men and Women. Cerebrovascular Diseases, 2005, 20, 291-298.	1.7	12
200	Sensitization of cerebrospinal fluid and peripheral blood lymphocytes to myelin basic protein in multiple sclerosis. Acta Neurologica Scandinavica, 1982, 66, 121-129.	2.1	12
201	Stroke Care in Central Eastern Europe: Current Problems and Call for Action. International Journal of Stroke, 2013, 8, 365-371.	5.9	12
202	Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 393-397.	1.2	12
203	Temporal trends in vascular risk factors and etiology of urban Polish stroke patients from 1995 to 2013. Journal of the Neurological Sciences, 2015, 357, 126-130.	0.6	12
204	Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases. Stroke, 2017, 48, 2263-2265.	2.0	12
205	Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA. Journal of Thrombosis and Thrombolysis, 2017, 44, 362-370.	2.1	12
206	Designing Clinical Trials in Wilsonâ€™s Disease. Hepatology, 2021, 74, 3460-3471.	7.3	12
207	Psychiatric disturbances as a first clinical symptom of Wilsonâ€™s disease â€“ case report.. Psychiatria Polska, 2016, 50, 337-344.	0.5	12
208	Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. Neurological Research, 1997, 19, 377-379.	1.3	11
209	APOE does not predict poor outcome 1 year after ischemic stroke. Neurological Research, 2007, 29, 64-69.	1.3	11
210	Organization of acute stroke services in Poland â€“ Polish Stroke Unit Network development. Neurologia I Neurochirurgia Polska, 2013, 47, 3-7.	1.2	11
211	Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN). Journal of the Neurological Sciences, 2016, 370, 237-240.	0.6	11
212	Mechanical thrombectomy in acute stroke â€“ Five years of experience in Poland. Neurologia I Neurochirurgia Polska, 2017, 51, 339-346.	1.2	11
213	Antiplatelet drugs and liver fibrosis. Platelets, 2022, 33, 219-228.	2.3	11
214	Brain magnetic resonance imaging and severity of neurological disease in Wilsonâ€™s disease â€” the neuroradiological correlations. Neurological Sciences, 2022, 43, 4405-4412.	1.9	11
215	Reduced binding of3H-spiroperidol to lymphocyte in Wilson's disease. Acta Neurologica Scandinavica, 1984, 69, 298-301.	2.1	10
216	The Polish Experience in Early Stroke Care. Cerebrovascular Diseases, 2003, 15, 14-15.	1.7	10

#	Article	IF	Citations
217	Are cognitive and behavioural deficits a part of the clinical picture in Kennedy's disease? A case study. Neurocase, 2009, 15, 332-337.	0.6	10
218	Lymphocyte subpopulations in the cerebrospinal fluid and peripheral blood in multiple sclerosis. Acta Neurologica Scandinavica, 1980, 62, 55-62.	2.1	10
219	Sunflower cataract: do not forget Wilson's disease. Practical Neurology, 2015, 15, 385-386.	1.1	10
220	Population-Specific Associations of Deleterious Rare Variants in Coding Region of P2RY1â€“P2RY12 Purinergic Receptor Genes in Large-Vessel Ischemic Stroke Patients. International Journal of Molecular Sciences, 2017, 18, 2678.	4.1	10
221	Prevention of ischemic stroke in clinical practice: a role of internists and general practitioners. Polish Archives of Internal Medicine, 2014, 124, 540-548.	0.4	10
222	Anti-myelin basic protein T cells protect hippocampal neurons against trimethyltin-induced damage. NeuroReport, 2007, 18, 425-429.	1.2	9
223	Care for patients after stroke. Results of a two-year prospective observational study from Mazowieckie province in Poland. Neurologia I Neurochirurgia Polska, 2010, 44, 231-237.	1.2	9
224	Effects of sling and voluntary constraint during constraint-induced movement therapy for the arm after stroke: a randomized, prospective, single-centre, blinded observer rated study. Clinical Rehabilitation, 2012, 26, 990-998.	2.2	9
225	Cerebrovascular reactivity and disease activity in relapsing-remitting multiple sclerosis. Advances in Clinical and Experimental Medicine, 2020, 29, 183-188.	1.4	9
226	Polish Forum for Prevention Guidelines on Hypertension: update 2017. Kardiologia Polska, 2017, 75, 282-285.	0.6	9
227	Analysis of 30-day stroke mortality in a community-based registry in Warsaw, Poland. Journal of Stroke and Cerebrovascular Diseases, 1994, 4, 63-67.	1.6	8
228	Pargyline pretreatment prevents immunological changes induced by MPTP in mice. Immunopharmacology, 1996, 35, 149-154.	2.0	8
229	Brain proton magnetic spectroscopy in long-term treatment of Wilsonâ€™s disease patients. Metabolic Brain Disease, 2010, 25, 325-329.	2.9	8
230	How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data?. International Journal of Stroke, 2010, 5, 430-431.	5.9	8
231	Influence of BDNF polymorphisms on Wilsonâ€™s disease susceptibility and clinical course. Metabolic Brain Disease, 2013, 28, 447-453.	2.9	8
232	Positivity of serum â€œclassicalâ€•onconeural antibodies in a series of 2063 consecutive patients with suspicion of paraneoplastic neurological syndrome. Journal of Neuroimmunology, 2013, 259, 75-80.	2.3	8
233	APOEÏµ2 allele is an independent risk factor for vulnerable carotid plaque in ischemic stroke patients. Neurological Research, 2014, 36, 950-954.	1.3	8
234	Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1017-1026.	1.6	8

#	Article	IF	Citations
235	Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurologia I Neurochirurgia Polska, 2018, 52, 98-101.	1.2	8
236	Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial. Translational Stroke Research, 2018, 9, 120-129.	4.2	8
237	Acute Ischemic Stroke Hospital Admissions, Treatment, and Outcomes in Poland in 2009â€“2013. Frontiers in Neurology, 2018, 9, 134.	2.4	8
238	Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence. Orphanet Journal of Rare Diseases, 2019, 14, 167.	2.7	8
239	Difficulties in diagnosis and treatment of Wilson diseaseâ€”a case series of five patients. Annals of Translational Medicine, 2019, 7, S73-S73.	1.7	8
240	Liver transplantation as a treatment for Wilsonâ€™s disease with neurological presentation: a systematic literature review. Acta Neurologica Belgica, 2022, 122, 505-518.	1.1	8
241	Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke. International Journal of Molecular Sciences, 2022, 23, 4530.	4.1	8
242	Subacute sclerosing panencephalitis: influence of the clinical course and treatment with isoprinosine on non-specific cell-mediated and humoral immunity. Acta Neurologica Scandinavica, 1983, 67, 275-284.	2.1	7
243	Stroke Service in Central and Eastern Europe. International Journal of Stroke, 2007, 2, 276-278.	5.9	7
244	Prestroke Antihypertensive Therapy: Effect on the Outcome. Clinical and Experimental Hypertension, 2013, 35, 141-147.	1.3	7
245	Transcranial sonography in mitochondrial membrane protein-associated neurodegeneration. Parkinsonism and Related Disorders, 2013, 19, 1061-1063.	2.2	7
246	Novel mutation of the NOTCH3 gene in a Polish family with CADASIL. Neurologia I Neurochirurgia Polska, 2016, 50, 262-264.	1.2	7
247	Gastropathy in patients with Wilson disease. Scandinavian Journal of Gastroenterology, 2020, 55, 14-17.	1.5	7
248	mtDNA depletionâ€like syndrome in Wilson disease. Liver International, 2020, 40, 2776-2787.	3.9	7
249	Polish Forum for Prevention Guidelines on Smoking: update 2017. Kardiologia Polska, 2017, 75, 409-411.	0.6	7
250	Wilsonâ€™s disease- management and long term outcomes. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 56-57, 101768.	2.4	7
251	D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilsonâ€™s Disease. Neurologia I Neurochirurgia Polska, 2021, 55, 595-597.	1.2	7
252	Differences between lymphocyte subsets of the cerebrospinal fluid in subacute sclerosing panencephalitis and acute aseptic meningitis. Journal of Neuroimmunology, 1981, 1, 173-181.	2.3	6

#	Article	IF	Citations
253	Factors predicting 30-day mortality in the Warsaw stroke registry. Journal of Stroke and Cerebrovascular Diseases, 1995, 5, 72-77.	1.6	6
254	EPITHETâ€"where next?. Lancet Neurology, The, 2008, 7, 570-571.	10.2	6
255	The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15Âyears. International Journal of Clinical Practice, 2015, 69, 180-185.	1.7	6
256	Differences in carotid artery atherosclerosis between men and women in the early phase after ischemic event. Neurologia I Neurochirurgia Polska, 2018, 52, 162-167.	1.2	6
257	Diagnosis of Wilson Disease and Its Phenotypes by Using Artificial Intelligence. Biomolecules, 2021, 11, 1243.	4.0	6
258	Prediction of Recovery and Outcome Using Motor Evoked Potentials and Brain Derived Neurotrophic Factor in Subacute Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105202.	1.6	6
259	A Double-Blind Controlled Trial of Naloxone in Early Treatment of Acute Ischemic Stroke. Cerebrovascular Diseases, 1992, 2, 40-43.	1.7	5
260	Three novel mutations (P760L, L1305P, Q1351Stop) causing Wilson disease. Human Mutation, 2001, 17, 156-156.	2.5	5
261	Downâ€regulation of microglia and NG2â€positive cells reaction in trimethyltinâ€injured hippocampus of rats treated with myelin basic proteinâ€reactive T cells: Possible contribution to the neuroprotective effect of T cells. Journal of Neuroscience Research, 2010, 88, 24-32.	2.9	5
262	Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients. Immunopharmacology and Immunotoxicology, 2010, 32, 416-421.	2.4	5
263	Wilson's disease: does iron metabolism impact phenotypic presentation?. Liver International, 2012, 32, 869-870.	3.9	5
264	Treatment of Wilsonâ€™s disease â€“ another point of view. Expert Opinion on Orphan Drugs, 2015, 3, 239-243.	0.8	5
265	Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013. Archives of Medical Science, 2016, 4, 754-759.	0.9	5
266	Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome. International Journal of Clinical Practice, 2016, 70, 477-481.	1.7	5
267	Adding transcutaneous electrical nerve stimulation to visual scanning training does not enhance treatment effect on hemispatial neglect: a randomized, controlled, double-blind study. Topics in Stroke Rehabilitation, 2016, 23, 377-383.	1.9	5
268	Transcranial Sonography in Mitochondrial Membrane Protein-Associated Neurodegeneration. Clinical Neuroradiology, 2018, 28, 385-392.	1.9	5
269	Induction of fiber outgrowth in PC12 pheochromocytoma cells by a neuronotrophic factor occurring in human tumors. Acta Neuropathologica, 1981, 53, 221-225.	7.7	4
270	Thrombolysis for Stroke in Poland: First 2 Years of Experience. International Journal of Stroke, 2006, 1, 111-112.	5.9	4

#	Article	IF	Citations
271	Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs-associated outcomes in real-world practice â€“ findings from the Polish Hospital Stroke Registry. Neurologia I Neurochirurgia Polska, 2013, 47, 517-524.	1.2	4
272	Pharmacotherapy prior to and in acute ischaemic stroke. The use of pharmacotherapy and drugs-associated outcomes in real-world practice â€“ findings from the Polish Hospital Stroke Registry. Neurologia I Neurochirurgia Polska, 2013, 47, 509-516.	1.2	4
273	Multiple sclerosis in two patients with coexisting Wilson's disease. Multiple Sclerosis and Related Disorders, 2014, 3, 387-390.	2.0	4
274	TMSâ€induced motor evoked potentials in Wilson's disease: A systematic literature review. Bioelectromagnetics, 2015, 36, 255-266.	1.6	4
275	Noninfectious complications of acute stroke and their impact on hospital mortality in patients admitted to a stroke unit in Warsaw from 1995 to 2015. Neurologia I Neurochirurgia Polska, 2018, 52, 168-173.	1.2	4
276	Oral Chelator Treatment of Wilson Disease. , 2019, , 357-364.		4
277	Fluoxetine for stroke recovery improvement â€“ the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia I Neurochirurgia Polska, 2020, 54, 544-551.	1.2	4
278	PENICILLAMINE IN MULTIPLE SCLEROSIS. Acta Neurologica Scandinavica, 1976, 54, 281-286.	2.1	3
279	Silent cerebrovascular lesions in patients with first-ever stroke. Journal of Stroke and Cerebrovascular Diseases, 1994, 4, 71-74.	1.6	3
280	Early stroke-related DVT is more than just DVT diagnosed early after stroke onset. Thrombosis Research, 2011, 128, 587-589.	1.7	3
281	Planning trials in older patients with stroke: data from the International Stroke Trial. Age and Ageing, 2011, 40, 395-398.	1.6	3
282	Do silent infarcts modify the effect of thrombolysis for stroke?. Acta Neurologica Scandinavica, 2013, 127, 227-232.	2.1	3
283	Venous thromboembolism prophylactic methods in acute stroke patients â€“ current state of knowledge. Neurologia I Neurochirurgia Polska, 2013, 47, 564-571.	1.2	3
284	Is there a bad time for intravenous thrombolysis? The experience of Polish stroke centers. Neurologia I Neurochirurgia Polska, 2014, 48, 45-51.	1.2	3
285	Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. Neurological Sciences, 2020, 41, 2605-2612.	1.9	3
286	Clinical significance of self-descriptive apathy assessment in patients with neurological form of Wilsonâ€™s disease. Neurological Sciences, 2021, , 1.	1.9	3
287	Increased burden of rare deleterious variants of the KCNQ1 gene in patients with largeâ€‘vessel ischemic stroke. Molecular Medicine Reports, 2019, 19, 3263-3272.	2.4	3
288	Sleep disturbances in newly diagnosed treatment-naÃ¯ve patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2022, 122, 745-751.	1.1	3

#	Article	IF	Citations
289	The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis. Molecular Neurobiology, 2022, 59, 4651-4668.	4.0	3
290	IMMUNOLOGY OF LESCH-NYHAN SYNDROME. Lancet, The, 1976, 307, 863.	13.7	2
291	Interpretation of IST and CAST stroke trials. Lancet, The, 1997, 350, 441-442.	13.7	2
292	Heart disease contributes to high stroke mortality in Poland. Journal of Stroke and Cerebrovascular Diseases, 2000, 9, 76-78.	1.6	2
293	Development of early comprehensive stroke inpatient rehabilitation in Poland â€“ current status and future requirements. Neurologia I Neurochirurgia Polska, 2011, 45, 245-251.	1.2	2
294	Infections Diagnosed after Admission to a Stroke Unit and Their Impact on Hospital Mortality in Poland from 1995 to 2015. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1775-1782.	1.6	2
295	Treatment of Wilsonâ€™s disease â€“ an update. Expert Opinion on Orphan Drugs, 2019, 7, 287-294.	0.8	2
296	Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016. Kardiologia Polska, 2017, 75, 187-190.	0.6	2
297	Autonomic nervous system dysfunction in Wilson's disease â€“ A systematic literature review. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102890.	2.8	2
298	Polish Forum for Prevention Guidelines on Cardiovascular Risk Assessment: update 2016. Kardiologia Polska, 2017, 75, 84-86.	0.6	2
299	Assessment of brain cortical atrophy in neurodegenerative as well as selected neurological disorders â€“ assessment methods and significance in diagnosis. Neuropsychiatria I Neuropsychologia, 2017, 1, 20-29.	0.4	1
300	Neuropsychiatric presentation of Wilsonâ€™s disease â€“ a case report. Neuropsychiatria I Neuropsychologia, 2018, 13, 31-42.	0.4	1
301	Neurological Wilson Disease. , 2019, , 145-157.		1
302	Clinical and laboratory parameters by age for patients diagnosed with multiple sclerosis between 2000 and 2015. Neurologia I Neurochirurgia Polska, 2021, 55, 387-393.	1.2	1
303	Polish Forum for Prevention Guidelines on Prophylactic Pharmacotherapy: update 2017. Kardiologia Polska, 2017, 75, 508-511.	0.6	1
304	Polish Forum for Prevention Guidelines on Diabetes: update 2017. Kardiologia Polska, 2017, 75, 628-631.	0.6	1
305	Blink reflex in newly diagnosed and treated patients with Wilsonâ€™s disease. Journal of Neural Transmission, 2021, 128, 1873-1880.	2.8	1
306	Brain proton magnetic spectroscopy in long-term treatment of Wilsonâ€™s disease patients. Metabolic Brain Disease, 2010, 25, 375-379.	2.9	0

#	Article	IF	Citations
307	A survey to establish current methods of venous thromboembolism prophylaxis in stroke patients practiced by Polish neurologists. Archives of Medical Science, 2014, 3, 470-476.	0.9	0
308	Jak postÄ™powaÄ‡ w zwÄ™Å¼eniu tÄ™tnic szyjnych u kobiet? KrÃ³tki przeglÄ…d wybranych badaÅ„ i wytycznych. Postepy Psychiatrii I Neurologii, 2014, 23, 156-161.	0.2	0
309	Disorders resulting from transporter defects. , 2016, , 687-693.		0
310	Transcranial sonography changes in patients with Wilsonâ€™s Disease during de-coppering therapy. Neurologia I Neurochirurgia Polska, 2020, 54, 185-192.	1.2	0
311	Perspectives of Wilsonâ€™s disease treatment. Pharmacotherapy in Psychiatry and Neurology, 2021, 37, .	0.1	0
312	Liver injury in Wilson's disease: An immunohistochemical study. Advances in Medical Sciences, 2022, 67, 203-207.	2.1	0